• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

眼周鳞状细胞癌

Periocular squamous cell carcinoma.

作者信息

Thosani Maya K, Schneck Gideon, Jones Evan C

机构信息

Department of Dermatology, Stony Brook University Medical Center, Stony Brook, New York 11733, USA.

出版信息

Dermatol Surg. 2008 May;34(5):585-99. doi: 10.1111/j.1524-4725.2007.34115.x. Epub 2008 Jan 31.

DOI:10.1111/j.1524-4725.2007.34115.x
PMID:18248482
Abstract

BACKGROUND

We present a case report of periocular squamous cell carcinoma and a review of the literature with emphasis on early diagnosis, proper follow-up and management, reconstructive options, and new immunomodulatory therapies.

OBJECTIVE

The objective is to guide the dermatologist and the dermatologic surgeon in proper management and continued care of patients with periocular squamous cell carcinoma in light of its propensity for perineural involvement and regional lymphatic metastases.

MATERIALS AND METHODS

A MEDLINE, Ovid, and PubMed search was conducted for recent relevant articles pertaining to "periocular,""periorbital,""squamous cell" carcinoma, and their "surgery""treatment" modalities.

CONCLUSIONS

Periocular squamous cell carcinoma is an aggressive tumor, characterized by perineural involvement and an overall rate of regional lymph node metastases reported to range from 10% to as high as 20% to 25%. Increased vigilance must be undertaken when treating these high-risk tumors. Mohs micrographic surgery or excision with frozen section analysis is the standard of care for periocular squamous cell carcinoma. Multiple options exist for the reconstruction of the postoperative defect that allow for excellent function and cosmesis. Finally, research into new immunomodulators will hopefully lead to an increased understanding of the aggressive nature of periocular squamous cell carcinoma and potential aid in the treatment of the tumor.

摘要

背景

我们报告一例眼周鳞状细胞癌病例,并对文献进行综述,重点关注早期诊断、恰当的随访与管理、重建方案以及新的免疫调节疗法。

目的

鉴于眼周鳞状细胞癌有神经周围侵犯和区域淋巴结转移的倾向,旨在指导皮肤科医生和皮肤科外科医生对眼周鳞状细胞癌患者进行恰当的管理和持续护理。

材料与方法

在MEDLINE、Ovid和PubMed数据库中检索近期与“眼周”“眶周”“鳞状细胞”癌及其“手术”“治疗”方式相关的文章。

结论

眼周鳞状细胞癌是一种侵袭性肿瘤,其特征为神经周围侵犯,区域淋巴结转移的总体发生率据报道在10%至高达20%至25%之间。治疗这些高危肿瘤时必须提高警惕。莫氏显微外科手术或切除加冰冻切片分析是眼周鳞状细胞癌的标准治疗方法。术后缺损的重建有多种选择,可实现良好的功能和美容效果。最后,对新免疫调节剂的研究有望增进对眼周鳞状细胞癌侵袭性本质的理解,并可能有助于肿瘤治疗。

相似文献

1
Periocular squamous cell carcinoma.眼周鳞状细胞癌
Dermatol Surg. 2008 May;34(5):585-99. doi: 10.1111/j.1524-4725.2007.34115.x. Epub 2008 Jan 31.
2
Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma.眼睑及眼周鳞状细胞癌患者的区域和远处转移模式
Ophthalmology. 2004 Oct;111(10):1930-2. doi: 10.1016/j.ophtha.2004.02.009.
3
The Australian Mohs database: periocular squamous intraepidermal carcinoma.澳大利亚莫氏手术数据库:眼周鳞状表皮内癌
Ophthalmology. 2004 Oct;111(10):1925-9. doi: 10.1016/j.ophtha.2004.04.025.
4
The Australian Mohs database: periocular squamous cell carcinoma.澳大利亚莫氏手术数据库:眼周鳞状细胞癌
Ophthalmology. 2004 Apr;111(4):617-23. doi: 10.1016/j.ophtha.2003.07.020.
5
Combined sentinel lymphadenectomy and mohs micrographic surgery for high-risk cutaneous squamous cell carcinoma.前哨淋巴结切除术联合莫氏显微外科手术治疗高危皮肤鳞状细胞癌
J Am Acad Dermatol. 2000 Sep;43(3):483-8. doi: 10.1067/mjd.2000.106367.
6
Treatment of basal cell carcinoma and squamous cell carcinoma with perineural invasion.伴有神经周围浸润的基底细胞癌和鳞状细胞癌的治疗
Adv Dermatol. 1993;8:277-304; discussion 305.
7
Management and reconstruction of periocular malignancies.眼周恶性肿瘤的管理与重建
Facial Plast Surg. 2007 Aug;23(3):181-9. doi: 10.1055/s-2007-984558.
8
Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia II. Perineural invasion.澳大利亚Mohs显微外科手术治疗皮肤鳞状细胞癌II. 神经周围浸润
J Am Acad Dermatol. 2005 Aug;53(2):261-6. doi: 10.1016/j.jaad.2005.03.048.
9
Linear basal cell carcinoma: a distinct clinical entity in the periocular region.线性基底细胞癌:眼周区域一种独特的临床实体。
Ophthalmology. 2006 Feb;113(2):338-42. doi: 10.1016/j.ophtha.2005.04.035. Epub 2006 Jan 10.
10
Skin cancer: a review with consideration of treatment options including Mohs micrographic surgery.皮肤癌:一篇考虑包括莫氏显微外科手术在内的治疗选择的综述
Ohio Med. 1990 Oct;86(10):745-7.

引用本文的文献

1
Cutaneous Squamous Cell Carcinoma on the Eyebrow of a Woman: A Rare Case Report.一名女性眉部皮肤鳞状细胞癌:罕见病例报告
Cureus. 2024 Jul 26;16(7):e65447. doi: 10.7759/cureus.65447. eCollection 2024 Jul.
2
Diagnosis and treatment of malignant eyelid tumors.恶性眼睑肿瘤的诊断与治疗。
Ophthalmologie. 2024 Jan;121(Suppl 1):33-39. doi: 10.1007/s00347-023-01945-y. Epub 2023 Oct 18.
3
Immune Checkpoint Inhibitor Therapy for Orbital and Ocular Adnexal Squamous Cell Carcinomas: International Society of Ocular Oncology President's Lecture, 2022.
免疫检查点抑制剂治疗眼眶和眼附属器鳞状细胞癌:国际眼肿瘤学会主席演讲,2022 年。
Invest Ophthalmol Vis Sci. 2023 Jun 1;64(7):29. doi: 10.1167/iovs.64.7.29.
4
[Diagnosis and treatment of malignant eyelid tumors].[恶性眼睑肿瘤的诊断与治疗]
Ophthalmologie. 2023 Mar;120(3):262-270. doi: 10.1007/s00347-023-01820-w. Epub 2023 Feb 9.
5
Reproducibility of Three-Dimensional Volumetric Measurement of Periocular Tumor Models.眼周肿瘤模型三维体积测量的可重复性
Ophthalmol Ther. 2023 Feb;12(1):111-123. doi: 10.1007/s40123-022-00595-8. Epub 2022 Oct 16.
6
Correlations between eyelid tumors and tear lipocalin, lysozyme and lactoferrin concentrations in postmenopausal women.绝经后女性眼睑肿瘤与泪液脂质运载蛋白、溶菌酶及乳铁蛋白浓度之间的相关性
J Med Life. 2015 Jan-Mar;8(1):94-8.
7
Cutaneous squamous cell carcinoma of the eyelid masquerading as a chalazion.
Int Ophthalmol. 2015 Feb;35(1):131-4. doi: 10.1007/s10792-014-0025-7. Epub 2014 Dec 6.
8
Massive periocular squamous cell carcinoma engulfing the globe: a rare case report.巨大的眶周鳞状细胞癌包绕眼球:一例罕见病例报告
Case Rep Oncol Med. 2014;2014:641086. doi: 10.1155/2014/641086. Epub 2014 Jul 24.
9
Ocular lymphatics: state-of-the-art review.眼部淋巴管:最新综述
Lymphology. 2009 Jun;42(2):66-76.